# Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI

> **NCT04951856** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 2166 (estimated)

## Conditions studied

- STEMI - ST Elevation Myocardial Infarction
- NSTEMI - Non-ST Segment Elevation MI

## Interventions

- **DRUG:** Evolocumab 140 MG/ML
- **DRUG:** Standard of care (SOC)

## Key facts

- **NCT ID:** NCT04951856
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-29
- **Primary completion:** 2026-05-22
- **Final completion:** 2028-05-22
- **Target enrollment:** 2166 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951856, "Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04951856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*